FMC (NYSE:FMC – Free Report) had its target price hoisted by Mizuho from $64.00 to $70.00 in a research report report published on Friday morning, Benzinga reports. They currently have a neutral rating on the basic materials company’s stock.
FMC has been the topic of several other reports. Barclays boosted their price target on shares of FMC from $62.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Monday, August 5th. KeyCorp lowered their target price on FMC from $81.00 to $79.00 and set an “overweight” rating on the stock in a research report on Friday, August 2nd. Wells Fargo & Company lowered their target price on FMC from $68.00 to $62.00 and set an “equal weight” rating on the stock in a research report on Tuesday, July 16th. JPMorgan Chase & Co. lifted their target price on FMC from $50.00 to $59.00 and gave the company a “neutral” rating in a research report on Monday, August 12th. Finally, Redburn Atlantic raised FMC from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 19th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, FMC presently has a consensus rating of “Hold” and an average target price of $68.00.
Check Out Our Latest Report on FMC
FMC Price Performance
FMC (NYSE:FMC – Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The basic materials company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.20. FMC had a net margin of 34.93% and a return on equity of 7.68%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the business earned $0.44 EPS. The firm’s revenue was up 8.5% on a year-over-year basis. On average, equities research analysts forecast that FMC will post 3.3 earnings per share for the current year.
Hedge Funds Weigh In On FMC
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Mather Group LLC. boosted its stake in FMC by 250.6% during the 3rd quarter. Mather Group LLC. now owns 554 shares of the basic materials company’s stock valued at $37,000 after purchasing an additional 396 shares during the last quarter. LRI Investments LLC purchased a new position in shares of FMC during the first quarter valued at approximately $41,000. UMB Bank n.a. boosted its position in shares of FMC by 56.9% during the second quarter. UMB Bank n.a. now owns 678 shares of the basic materials company’s stock valued at $39,000 after buying an additional 246 shares during the last quarter. Sentry Investment Management LLC purchased a new position in shares of FMC during the first quarter valued at approximately $45,000. Finally, EntryPoint Capital LLC boosted its position in shares of FMC by 1,282.3% during the first quarter. EntryPoint Capital LLC now owns 857 shares of the basic materials company’s stock valued at $55,000 after buying an additional 795 shares during the last quarter. Institutional investors own 91.86% of the company’s stock.
FMC Company Profile
FMC Corporation, an agricultural sciences company, provides crop protection, plant health, and professional pest and turf management products. It develops, markets, and sells crop protection chemicals that includes insecticides, herbicides, and fungicides; and biologicals, crop nutrition, and seed treatment products, which are used in agriculture to enhance crop yield and quality by controlling a range of insects, weeds, and diseases, as well as in non-agricultural markets for pest control.
Further Reading
- Five stocks we like better than FMC
- Why Invest in High-Yield Dividend Stocks?
- Intel: Is Now the Time to Be Brave?Â
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Stock Market Index and How Do You Use Them?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for FMC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FMC and related companies with MarketBeat.com's FREE daily email newsletter.